Table 1 Performance of the 7-AAb panel and AFP in HCC detection
From: Autoantibody signature in hepatocellular carcinoma using seromics
Phase | Detectiona | HCC vs. (healthy + cirrhotic) | HCC vs. healthy | HCC vs. cirrhotic | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
AUC | Specificity | Sensitivity | AUC | Specificity | Sensitivity | AUC | Specificity | Sensitivity | ||
Test Phase (II) | AFP | 0.808 | 98.7% | 28.4% | 0.821 | 100.0% | 28.4% | 0.789 | 96.7% | 28.4% |
ANN | 0.894 | 92.1% | 68.6% | 0.933 | 93.3% | 77.5% | 0.838 | 90.2% | 61.6% | |
AFP + ANN | 0.924 | 92.1% | 78.6% | 0.959 | 96.3% | 84.1% | 0.873 | 92.4% | 71.6% | |
Validation Phase (III) | AFP | 0.822 | 99.6% | 30.7% | 0.822 | 100.0% | 30.7% | 0.823 | 98.8% | 30.7% |
ANN | 0.902 | 90.1% | 73.4% | 0.928 | 93.4% | 77.5% | 0.853 | 96.3% | 62.2% | |
AFP + ANN | 0.932 | 90.1% | 82.0% | 0.953 | 93.4% | 83.9% | 0.893 | 95.1% | 73.0% | |
Test phase (II) + validation phase (III) | AFP | 0.815 | 99.1% | 29.6% | 0.821 | 100.0% | 29.6% | 0.805 | 97.7% | 29.6% |
ANN | 0.898 | 90.0% | 71.6% | 0.930 | 92.7% | 77.7% | 0.845 | 90.8% | 64.1% | |
AFP + ANN | 0.928 | 93.7% | 77.0% | 0.956 | 93.4% | 85.1% | 0.882 | 91.3% | 73.0% | |